BEDMINSTER, N.J. and SINGAPORE, May 17 (Bernama-GLOBE NEWSWIRE) — Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being co-developed by Baylor College Medicine and Tessa. The data is from an ongoing Phase 1 dose-escalation study (NCT04288726) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021).
The presentation at ASGCT 2021 will highlight data from six patients treated with the therapy. The results demonstrated a favorable safety profile with encouraging clinical activity even at lower dose levels in heavily pre-treated relapsed / refractory (R/R) CD30+ lymphoma patients. The dataset includes three patients dosed at the lowest dosing level (4 × 107 CD30.CAR EBVSTs) and three at the second level (1 × 108 CD30.CAR EBVSTs). Key findings summarized below: